Stockwatch: Reheating the burnt offering
This article was originally published in Scrip
Executive Summary
As the board of the Chinese biotechnology company 3SBio considers the offer from a local consortium that includes their chairman and CEO to take the company back into private ownership (scripintelligence.com, 14 September 2012), shareholders may well appreciate a retrospective on how well take-private transactions have fared at other biotechnology companies.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.